Following are answers to some of the common questions most asked by journalists. For more information about Geron, please visit the pages on this site focused on our products, technology and science and investor information.
Q: Who is Geron? A: Geron is a biotech company developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes. The company is advancing an anti-cancer drug and a cancer vaccine that target the enzyme telomerase through multiple clinical trials in different cancers.
Q: How large is Geron? A: Geron has more than 175 employees. It has a wholly-owned subsidiary, Geron Bio-Med Limited, located in Edinburgh, Scotland and a majority-owned subsidiary, TA Therapeutics, Limited, located in Hong Kong.
Q: Are logos and photos of Geron available? A: Photos and logos of Geron and our products are available. Please contact our media relations department at 650-473-7765 or via email at info@geron.com.
Q: Do you have b-roll footage available? A: Yes, we have broadcast-quality b-roll available for journalists. Please contact our media relations department at 650-473-7765 or via email at info@geron.com.
Q: Where is Geron's headquarters? A: Geron's headquarters are located 230 Constitution Drive, Menlo Park, CA 94025. The main phone number is 650-473-7700 and the main fax number is 650-473-7750.
Q: I'm working on a story about Geron and would like to arrange an interview with a Geron spokesperson. How do I go about that? A: Please contact our media relations department at 650-473-7765 or via email at info@geron.com.
Q: Where is Geron incorporated? A: Geron is incorporated in the State of Delaware since November 1990.
Q: When did Geron go public? A: Geron went public in July 1996.
Media and Investor Relations
Geron Corporation
230 Constitution Drive
Menlo Park, CA 94025
Tel: 650-473-7765
Email: info@geron.com
